High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection

Open Forum Infectious Diseases

Volumn 1, Issue 3, 2014, Pages

  Lo, Janet ^a   Rosenberg, Eric S ^a   Fitzgerald, Michael L ^a   Bazner, Suzane B ^a   Ihenachor, Ezinne J ^a   Hawxhurst, Victoria ^a   Borkowska, Alison H ^a   Wei, Jeffrey ^a   Zimmerman, Chloe O ^a   Burdo, Tricia H ^b   Williams, Kenneth C ^b   Freeman, Mason W ^a   Grinspoon, Steven K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON COLLEGE   (United States)

Author keywords

Acute HIV infection; Antiretroviral therapy; Atherosclerosis; Cholesterol efflux; Inflammation

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN B; CD14 ANTIGEN; CD163 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL EFFLUX; CLINICAL ARTICLE; CONTROLLED STUDY; EFFUSION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

EID: 84978328510     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu108     Document Type: Article

References (31)

1. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr 2003; 33:506-12.
2. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
3. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-53.
4. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
5. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160:458-67.
6. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
7. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336-45.
8. Asztalos BF, Mujawar Z, Morrow MP, et al. Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J Infect Dis 2010; 202:614-23.
9. Cui HL, Ditiatkovski M, Kesani R, et al. HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB J 2014; 28:2828-39.
10. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.
11. Lichterfeld M, Rosenberg ES. Acute HIV-1 infection: a call to action. Ann Intern Med 2013; 159:425-7.
12. Blasi E, Mathieson BJ, Varesio L, et al. Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature 1985; 318:667-70.
13. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med2011; 364:127-35.
14. Kramer HB, Lavender KJ, Qin L, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 2010; 6:e1000893.
15. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-54.
16. Annema W, Nijstad N, Tolle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 2010; 51:743-54.
17. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-45.
18. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181(Suppl 3):S462-72.
19. Feeney ER, McAuley N, O'Halloran JA, et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis 2013; 207: 628-37.
20. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-12.
21. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737-46.
22. Centlivre M, Legrand N, Steingrover R, et al. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol 2011; 89:785-95.
23. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011; 204:154-63.
24. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-36.
25. Martin GE, Gouillou M, Hearps AC, et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
26. Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces agerelated changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-53.
27. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104:1041-50.
28. Kawamura A, Miura S, Fujino M, et al. CXCR3 chemokine receptorplasma IP10 interaction in patients with coronary artery disease. Circ J 2003; 67:851-4.
29. Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113:2301-12.
30. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44:2137-41.
31. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86.